Mohammad AskarPublic working copy · medical review pending

Sickle retinopathy and macular oedema · 186

Sickle cell retinopathy and cystoid macular oedema

Separate peripheral proliferative disease, macular ischaemia and oedema before selecting treatment.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Genotype informs risk, but examination and imaging determine the eye’s current problem. Treat the cause of oedema rather than the OCT cavity alone.

Terminology and draft status

Terminology review is not complete. No new WHO UMD entry verification is claimed for this copy; pending entries and limits are recorded in terminology.md.

01Connect genotype with vascular injury

Sickle cell disease is an inherited haemoglobinopathy, not a single uniform retinal phenotype. HbS involves glutamate-to-valine substitution in beta-globin; HbSC combines HbS with a different HbC variant and must not be described as two identical mutations. Deoxygenation promotes HbS polymerisation, red-cell rigidity and vaso-occlusion. Haemolysis and vascular dysfunction also contribute; peripheral oxygen physiology alone does not explain every lesion. 1

HbSS often causes more severe systemic anaemia and vaso-occlusive complications, while proliferative retinopathy can be more frequent in HbSC despite milder systemic disease. Macular ischaemia and peripheral proliferation can occur in either genotype; neither pattern can be assigned exclusively from the blood label. Coordinate the ocular assessment with haematology and review systemic treatment and surgical risks. 1

02Locate the sea fan and its complications

Goldberg stages describe peripheral disease:1 peripheral arteriolar occlusion,2 arteriovenous anastomoses,3 neovascular sea fans,4 vitreous haemorrhage and5 retinal detachment. Detachment may be tractional, rhegmatogenous or combined. The Gorgonia analogy describes a fan-shaped vessel network, not a separate diagnosis. Document perfusion and activity because sea fans can autoinfarct and an old lesion does not prove current leakage. 1

Salmon patches are haemorrhagic lesions, iridescent spots are residual changes after blood breakdown and black sunbursts reflect pigment/RPE response around prior haemorrhage. The export’s single fixed layer and haemosiderin explanation is too restrictive. Describe actual depth and appearance with examination/OCT; these signs support the clinical context but do not replace haemoglobin testing or exclude another retinal cause. 1

03Look for silent macular ischaemia

Capillary loss and temporal/segmental retinal thinning can occur despite visual acuity1.0 and a preserved foveal depression. OCT-A is useful for flow patterns but can confuse low flow or artefact with nonperfusion; structural OCT and selected angiography remain complementary. The original20% below18years and>40–45% above40years lack an identified cohort/definition and are not universal prevalence or screening thresholds. 1

Established ischaemic tissue loss has no proven routine ocular treatment that restores it. Haematology may use hydroxyurea to raise fetal haemoglobin (HbF) and address systemic disease, but this is not a proven reversal of macular thinning or an automatic ocular prescription. Preserved central acuity is not proof of absence of disease; use an individualized retinal follow-up plan. 1

04Select treatment for proliferative risk

Selected active/high-risk stage3 sea fans may be treated with peripheral scatter laser; stage alone does not mandate identical laser for every eye. The2022 Cochrane review included3 trials,414eyes/339people, with low/very-low certainty and differing techniques; allocation/reporting limitations and eye-level analysis prevent a simple guarantee of preserved vision. The review does not establish the best modern anti-VEGF or surgical protocol. 1 2

Persistent vitreous haemorrhage, traction threatening the macula or retinal detachment may need vitrectomy. Avoid hypoxia, acidosis and unnecessary pressure stress through coordinated perioperative care. Anti-VEGF can be a selected adjunct but traction/contraction and timing matter; the original same-morning or one-day-preoperative rule is not validated for every sickle eye. Decide it with the operating retina and haematology teams. 1

05Identify what produces the cystoid spaces

Cystoid macular oedema (CMO/ZMO) is a pattern, not an aetiology. Blood–retina barrier leakage can produce spaces in the inner nuclear layer and outer plexiform/Henle region, but layer numbering5/6 depends on the anatomical convention. Not every OCT cavity is leaking oedema; degeneration and traction are alternatives. A petaloid FA pattern reflects anatomy and does not identify the cause alone. 1

Consider diabetes/vein occlusion, postoperative Irvine-Gass, uveitis or scleritis, inherited retinal disease and medicines. Irvine-Gass often appears around4–10weeks after cataract surgery, but earlier/later presentations occur. Optic-disc leakage (hot disk) can support postoperative inflammation, yet its presence is not specific and absence does not prove diabetic disease. Retinitis pigmentosa and gyrate atrophy may produce cystoid changes with little or no FA leakage, without making every such cavity irreversible atrophy. 1

Latanoprost/prostaglandin analogues, taxanes, nicotinic acid, MEK inhibitors and fingolimod enter the medication review. Neither pseudophakia alone nor a temporal association proves causation. The original stop-prostaglandin1week before/after surgery is not a universal schedule: balance inflammation/CMO risk against glaucoma pressure control and coordinate changes. An MEK-associated serous pattern is not identical to inflammatory CMO. 1

06Treat cause and function, not an isolated thickness

For selected Irvine-Gass use topical NSAIDs and/or corticosteroids; persistent disease may prompt specialist acetazolamide, local injection or other options after reassessment. Uveitic oedema requires exclusion of infection and coordinated inflammatory control; posterior sub-Tenon or intravitreal steroids carry pressure, cataract and infection risks. Diabetes-related oedema needs indication-specific anti-VEGF/steroid/laser assessment, not an automatic choice between any injection and surgery. 1

Carbonic anhydrase inhibitors may help selected retinitis-pigmentosa cystoid changes; intravitreal therapy is not categorically ineffective. Vitrectomy with possible ILM peeling is considered when traction or another operable mechanism contributes, not for every refractory oedema. The quoted20° slow peeling angle is an unvalidated technical teaching point, not a universal safety threshold. Hyperreflective foci and layer disruption can inform prognosis; they do not mean inevitable blindness or literally break through the ILM and photoreceptors. 1

Treat cause and function, not an isolated thickness
ConditionPatternManagementBoundary
Sickle stage3Sea fan/GorgoniaSelected peripheral laserAutoinfarction and activity must be assessed
Irvine-GassPetaloid FA±hot diskSelected NSAIDs/steroidsOften4–10weeks postoperatively;not diagnostic alone
Macular ischaemiaSegmental thinningHaematology/systemic care;hydroxyurea when indicatedCan coexist with acuity1.0;no proven reversal of thinning
Retinitis pigmentosaCystoid spaces±FA leakageSelected acetazolamide/other optionsNot every cavity is atrophy;IVI not universally futile
Latanoprost-associated CMOCystoid spaces with exposure contextCoordinate medicine review/changeCataract surgery alone does not prove causation
What are the main learning points?

Genotype informs risk, but examination and imaging determine the eye’s current problem. Treat the cause of oedema rather than the OCT cavity alone.

When is assessment urgent?

New floaters, flashes, a curtain or rapid visual loss requires urgent retinal assessment. Severe pain, redness or suspected infection also needs prompt care.

References and access status

  1. 1
    Immutable original export; sickle retinopathy/CMO lecture; examiner attribution unchecked

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    Cochrane2022 laser in proliferative sickle retinopathy, PMID36508693

    Actual indexed abstract methods/results/conclusions inspected16November2026;3trials414eyes/339people, eye-level/bias/certainty limits; direct PMC returned browser-check, full trials unread.

Original lecture link